Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals & M&A

Set Alert for Deals & M&A

Vifor Clinches Deal For Travere's Rare Kidney Disorder Drug

The Swiss group has delivered on its promise to secure more deals in the nephrology space by bagging the rights in Europe, Australia and New Zealand to sparsentan, which is deep into a Phase III program for focal segmental glomerulosclerosis and IgA nephropathy.

Renal Deals

Provepharm’s CEO Plans Fresh Acquisitions After Raising €120m

France’s Provepharm Life Solutions, which finds new uses for known mature molecules, in particular antidotes and surgical dyes, by improving their efficacy and maximizing their therapeutic potential, has fresh funds to expand its portfolio.

Business Strategies Clinical Trials

Chinese Biotechs' Foray Into mRNA Enters New Chapter With $100m Everest Deal

Everest Medicines’ deal with Canadian biotech Providence Therapeutics contains a full transfer of technology which may be appealing to Chinese regulators.

China Deals

Deal Watch: AzurRx Expands GI Pipeline With Buyout Of Partner First Wave

Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.

Deal Watch Deals

AbbVie Extends Reach Of Regenxbio’s Wet AMD Program

The partnership worth up to $1.75bn removes the significant risk of going it alone in a competitive market as Regenxbio awaits late-stage data for its gene therapy.

Deals Gene Therapy

Quick Listen: Scrip’s Five Must-Know Things

In this week's podcast edition of Scrip's Five Must-Know Things: US industry warns over pricing; a setback for another gene therapy; a Phase II disappointment for Novartis; Actemra shortages cause CAR-T worries; and Sweden's Sobi set to go private. 

Pricing Debate M & A

Merck KGaA In The Market For Bolt-On M&A

Belén Garijo, the German group's CEO, has told analysts she considers targeted smaller to medium-sized acquisitions to be more likely than major transformational deals but said that "we are always open to something bolder."

M & A Strategy

Genome & Co. Bets On Rosy Microbiome Outlook

Korean bioventure Genome & Co. is accelerating growth by acquiring US microbiome CDMO List Labs, following on from its purchase of US microbiome therapeutics firm Scioto last year. With its microbiome pipeline reaching milestones as planned, Genome appears on track for its goal of becoming a fully integrated global biopharma concern.

South Korea Biologics

Lilly To Try ProQR’s RNA-Editing Technology In Liver, Neurology Indications

ProQR’s Axiomer platform can enable single nucleotide RNA editing, an approach that could address thousands of disease-causing genetic mutations, the company says.

Deals Platform Technologies

Bone Therapeutics More Interested In A Partner Than A Buyer

Miguel Forte, Bone Therapeutics CEO, has told Scrip that another approach from French company Hybrigenics about a merger came as a surprise, adding that his priority is the expansion of the Belgian biotech's allogenic cell therapy platform after the recent failure of its Phase III asset for knee osteoarthritis pain.

M & A Regenerative Medicine

Sanofi’s Kadmon Bolt-On Bolsters Its General Medicine Division

Sanofi’s $1.9bn cash purchase of Kadmon surprised many analysts, coming as a bolt-on for the French pharma’s general medicines transplant portfolio rather than its specialty care pipeline, but the overall view was that it made sense.

M & A Companies

Roche Jumps Back Into Huntington’s With Spark/NeuExcell Partnership

Deal Snapshot: Roche gene therapy subsidiary Spark gets option and will partner with start-up NeuExcell on a Huntington’s gene therapy that researchers say may regenerate functional neurons.

Deals Gene Therapy
UsernamePublicRestriction

Register